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Introduction
Methotrexate (MTX), an anti-inflammatory and anti-
cancer agent, was shown to improve clinical symptoms
of rheumatoid arthritis (RA) as shown for the first time
in 1951 [1]. 
Recently, methotrexate (4-amino-N10-methyl ptero y l -
glutamic acid) is the most frequently used anti-rheumatic
drug [2, 3]. Therapeutic effect of MTX in inflammatory
rheumatic conditions and in animal models of experimental
arthritis seems to be associated with its anti-inflammatory
properties rather than with anti-proliferative mechanism of
action. Several pharmacological mechanisms of action of
MTX have been suggested so far, however, despite well
documented facts there are still many controversies. There
is some evidence, that MTX, a folate antagonist, 
may prevent de novo pyrimidine and purine synthesis
consequently inhibiting production of DNA, RNA and
proliferation of cells [4]. Most studies describe a dose-
dependent induction of apoptosis and/or reduction of cell
proliferation by MTX [5]. It has been suggested that MTX
induces apoptosis only in activated cells [6]. Interestingly,
MTX differentially affects monocytic cell lines and
lymphocytes [5, 7]. 
In RA the rapid clinical remission after MTX
application may indicate endogenous alterations in the
production of cytokines [4, 8, 9] and/or humoral responses
[10]. Methotrexate reduces in vivo the production of many
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cytokines (TNF-α, IL-4, IL-6, IFN-γ, and GM-CSF) 
[4, 8, 9]. On the other hand, MTX hardly affects cytokine
production by monocytes in vitro [8, 11]. 
Moreover, it has been shown that low-dose MTX-
treatment of RA patients results in the reduced serum
concentration of TNF-α, while ex vivo there is no difference
in the production of TNF-α by PHA-stimulated peripheral
blood mononuclear cell (PBMC) taken from RA patients and
controls [12]. In addition, Aggarwal and coworkers [13]
showed that 4 weeks MTX treatment has no effect on the
spontaneous production of cytokines in whole-blood cultures,
however after LPS stimulation IL-6 levels were lower in
MTX treated patients. MTX does not affect LPS-induced
release of IL-1 and TNF-α by monocyte cell lines [14].
Methotrexate also does not control in vitro LPS induced 
IL-1 synthesis by resident peritoneal macrophages [15]. 
As many studies on methotrexate immunosuppressive
properties seem to be inconclusive and generally
demonstrate little or no effect of MTX on cytokine
production in vitro, it rises the questions whether is it
a matter of:
• different target cells for MTX (macrophages vs. T cells
or synoviocytes as a source of cytokines),
• expression of different receptors for MTX in distinct
inflammatory loci,
• different regimes of MTX treatment used; e.g. low-dose
(anti-inflammatory) vs. high-dose (anti-cancer) treatment.
Therefore, in our study we have addressed the issue
whether expected beneficial therapeutic effect of high-dose
MTX treatment in CIA, a murine model of RA, will be
accompanied by suppression of cytokine production by any
inflammatory cells, including cells not involved directly in
the pathogenesis of arthritis. First of all, we wanted to
explain whether the production of proinflammatory
cytokines by peritoneal macrophages is resistant to MTX,
both in vitro and in vivo.
Material and methods
Reagents
Collagen type II (CII) from chicken sternal cartilage,
Complete Freund’s Adjuvant (CFA), methotrexate (MTX),
lipopolysaccharide (LPS) from Escherichia coli 0111:B4,
myeloperoxidase (MPO) from human leukocytes, hexade -
cyltrimethylammonium bromide (HTAB), o-dianisidine
dihydrochloride (OPD), hydrogen peroxide were all from
Sigma-Aldrich (USA). Horseradish peroxidase (HRP)
conjugated streptavidin was obtained from Vector (USA)
and bovine serum albumin (BSA) fraction V was from
Roche Diagnostics (Germany). 
Anti-mouse cytokine primary monoclonal antibodies:
rat anti-mouse IL-6 monoclonal antibody, rat anti-TNF-α
monoclonal antibody, rat anti-mouse IL-12p40 monoclonal
antibody were all from e-Bioscience (USA). OptEIA mouse
IL-10 set was from BD PharMingen (USA). Biotin
conjugated antibodies: anti-IgM, anti-IgG2a were from
SouthernBiotech (USA), anti-IgG1 from MP Biomedicals
(USA) and anti-IgG was from Sigma-Aldrich (USA).
Cytokines: recombinant mouse IL-6, recombinant mouse
IL-12p40, recombinant mouse TNF-α were all from 
e-Bioscience (USA). 
Mice
Inbred DBA/1J male mice and CBA mice were bred in
the Animal Breeding Unit, Department of Immunology,
Jagiellonian University College of Medicine, Krakow. Mice
were housed 4-5 per cage and maintained under clean
conventional conditions with free access to standard rodent
diet and water. Mice were used at 8 to 10 weeks of age. The
authors were granted permission by the Local Bioethical
Committee to use mice in presented study. Experiments
were conducted according to ethical guidance of Local
Bioethical Committee. 
Induction and evaluation of collagen induced
arthritis 
To induce collagen induced arthritis (CIA), DBA/1J mice
were injected intradermally with chicken collagen type II (CII,
200 µg/mouse) emulsified in Complete Freund’s Adjuvant
(CFA). 21 days later mice received boost intraperitoneal
injection of CII (100 µg/mouse) in the presence of LPS 
(5 µg/mouse). Starting from the second (booster) injection of
collagen, mice were examined visually every other day for
the incidence and severity of arthritis (joint swelling and
redness). Paw thickness was measured using Mitutoyo
micrometer. The lesions of the four paws were each graded
from 0 to 4 (CIA index) according to the increasing extend of
erythema and edema of the periarticular tissues.
Methotrexate treatment of collagen induced arthritis
Methotrexate (50 µg/mouse = ~2,5 mg/kg) was given
by intravenous injections three times a week for 3 weeks,
starting on day 21, the day of second immunization (see
Protocol – Fig. 1). Control animals (referred to as untreated)
received intravenous injection of saline. The regimen was
chosen to test the effect of high-dose MTX on cytokine
production by macrophages and was based on the protocol
described by Neurath et al. [16].
Measurement of myeloperoxidase activity
On day 42 (the end of experiment) hind paws were
collected and homogenized. Myeloperoxidase (MPO)
activity in articular tissues was measured according to
Bradley’s method [17]. The activity of MPO was calculated
from the MPO standard curve and expressed in units. One
unit of MPO activity was defined as that degrading 1 µmol
of hydrogen peroxide per minute at room temperature. Each
sample was measured in duplicate. 
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Measurement of serum anti-collagen antibody
titers
The blood was collected from mice on day 35 and 42
and the serum was prepared. Anti-CII antibodies in serum
were measured by sandwich ELISA as described previously
[18]. Shortly, plates (Costar EIA/RIA High Binding plates,
Corning Incorporated, USA) were coated with native
chicken collagen type II (5 µg/ml). Mouse serum diluted
geometrically in PBS was applied into collagen coated wells
followed with biotin-conjugated antibodies against IgM,
IgG, IgG1 and IgG2a. Horseradish peroxidase conjugated
streptavidin was used as detection reagent followed with
the o-phenylenediamine dihydrochloride (OPD) peroxidase
substrate. The antibody levels were expressed in arbitrary
ELISA units calculated from anti-CII immunoglobulin titer:
1 Unit = 1/100 titer of immunoglobulin specific to native
chicken collagen type II. 
Measurement of cytokine production by peritoneal
residual cells taken from DBA/1J mice 
On day 42 (the end of experiment) peritoneal residual
cells were collected and cultured at a cell density of 
5 × 105/ml for 24 h with or without LPS (100 ng/ml) 
(E. coli 0111:B4 cell wall component). The concentration
of cytokines (TNF-α, IL-6, IL-10, IL-12p40) in culture
supernatants was measured by sandwich cytokine ELISA. 
Short-term in vivo methotrexate treatment and its
effect on ex vivo cytokine production by peritoneal
macrophages of CBA mice 
Methotrexate (50 µg/mouse) was injected intravenously
on day 0, 2, 4 (7.5 mg/kg/week) to CBA mice, (referred to
as MTX treated mice). Control mice were injected with
saline (referred to as untreated mice). Thioglycollate was
given by intraperitoneal injection on day 4 (the day of the
Day 0
Day 35
CII (200 µg/mouse) + CFA, sc CII (100 µg/mouse) + LPS (5 µg/mouse), ip
• MTX (50 µg/mouse) every other day
• Arthritis Score by visual observation
and paw thickness measurement
• Final evaluation of arthritis
• Blood – serum anti-CII IgM, IgG, IgG2a, IgG1
• Peritoneal residual cells – culture – cytokines
• Hind paws – MPO activity in articular tissues






Fig. 1. Protocol of the CIA induction and MTX treatment 
Mice were immunized with type II chicken collagen (CII) in CFA (200 µg/mouse, day 0) followed with the second immunization with CII (100 µg/mouse) in the
presence of LPS (5 µg/mouse) 21 days later. MTX (50 µg/mouse, approx. 2.5 mg/kg) was injected intravenously (i.v.) every other day (three times a week) starting
from the day of the second immunization (day 21). During treatment clinical symptoms of arthritis were visually examined three times a week and the thickness of
the hind paws was measured at the same time. Two weeks after second immunization (day 35) blood was collected from all mice and the levels of anti-CII antibodies
(IgM, IgG, IgG1 and IgG2a) were determined in serum. One week later (on day 42) the experiment was completed. Mice were bled and sacrificed. Residual peritoneal
cavity cells were harvested for the in vitro culture and hind paws were collected for MPO assay. 
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last injection of MTX). Three days later peritoneal exuded
cells (mostly macrophages) were collected and cultured 
24 h in vitro with or without LPS (100 ng/ml). The cytokine
production was tested as described above.
In vitro effect of MTX on cytokine production by
macrophages
A. Peritoneal macrophages
Naïve CBA mice were injected intraperitoneally with
thioglycollate. Three days later peritoneal macrophages
were collected and cultured 24 h in vitro with different
concentrations of MTX (0, 1, 10, 100 µg/ml), with or
without LPS (100 ng/ml) or cells were cultured with
indicated amounts of MTX for 24 h and then medium was
replaced and LPS was added to the cultured cells for
additional 24 h. Cytokine production was measured in
culture supernatant by ELISA. 
B. RAW 264.7 – macrophage cell line
RAW 264.7 cells were cultured in vitro in the presence
of LPS (100 ng/ml) and different concentrations of MTX
(0, 1, 10, 100 µg/ml) for 24 h or cells were cultured for 
24 h in the presence of MTX and then stimulated with LPS
for additional 24 h. Cytokines were measured in the culture
supernatant by ELISA. 
Analysis of cytokine production in macrophage 
culture supernatant by ELISA
Cytokines in the culture supernatant were measured by
sandwich cytokine ELISA.
Statistical analysis
Student’s t-test was used to determine the significance
of group differences. A p-value less than 0.05 was
considered significant.
Results
The effect of methotrexate treatment on the 
development of CIA in DBA/1J mice
As expected, in mice treated with MTX (7.5 mg/kg/week)
the incidence of disease and the severity of arthritis evaluated
by the mean arthritis index, paw thickness and MPO activity
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Fig. 2. The effect of MTX on the development of CIA in DBA/1J mice 
A – The incidence of CIA: the percentage of the arthritic mice at the indicated times are shown. 
B – The severity of arthritis is expressed as the thickness of hind paws shown in mm (mean ± SEM) and the mean of the arthritis index of all CIA positive mice is shown
in parenthesis. [x] – arthritis index;  – placebo (n = 8);  – MTX (n = 10). 
C – The level of MPO measured in joint tissue of hind paws is shown as the mean of all CIA positive mice in units [U] per mg of protein obtained from hind paws.




Day of the experiment
Central European Journal of Immunology 2010; 35(3)132
Methotrexate treatment markedly decreased the serum
levels of anti-CII antibodies (IgM, IgG, IgG2a and IgG1).
The production of both anti-CII IgG2a, the indicator of
Th1 response, and anti-IgG1, the indicator of Th2
response, were inhibited by high dose of MTX to the same
extend (Fig. 3).
The effect of methotrexate treatment on the 
production of cytokines by residual peritoneal cells
of DBA/1J mice 
Methotrexate treatment did not affect the spontaneous
ex vivo cytokine production by residual peritoneal cells of
DBA/1J mice (data not shown). Surprisingly, cells taken
from MTX-treated mice and stimulated in vitro with LPS,
showed higher production of proinflammatory cytokines
(TNF-α, IL-6 and IL-12p40) as compared to the peritoneal
cells of untreated mice, while IL-10 production was not
affected by MTX-treatment (Fig. 4). 
The effect of short time in vivo methotrexate
treatment on the cytokine production by
thioglycollate-induced peritoneal macrophages of
CBA mice 
Short term in vivo MTX treatment did not affect the
spontaneous ex vivo cytokine production by thioglycollate-
induced peritoneal macrophages. However, in response to
in vitro stimulation with LPS of cells taken from mice
treated with MTX in vivo (3 intravenous injections of MTX,
50 µg/mouse) produced more proinflammatory cytokines
(IL-6, TNF-α and IL-12p40) than cells taken from untreated
mice (saline injected mice) (Fig. 5).
In vitro effect of methotrexate on cytokine production
by thioglycollate-induced CBA peritoneal
macrophages 
When thioglycollate-induced peritoneal macrophages
from naïve CBA mice were cultured in vitro with LPS and






























Fig. 3. The effect of MTX on CII specific antibodies in serum 
The level of anti-CII antibodies (IgM, IgG, IgG1 and IgG2a) was measured in serum one week after boost immunization, on day 35 (D35) and on day 42 (D42), at
the end of the experiment. Bars show the mean ± SEM; white bars – placebo, black bars – MTX treated mice; *p < 0.05, **p < 0.01; ***p < 0.001 MTX treated
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Fig. 4. The effect of MTX on the production of cytokines by peritoneal cells of DBA/1J mice 
Residual peritoneal cells of MTX treated and untreated DBA/1J mice were cultured in vitro for 24 h in the presence of LPS (100 ng/ml). IL-6, TNF-α, IL-10 and 


















different concentrations of MTX (1-100 µg/ml), MTX had
no effect on LPS-induced cytokine production by these cells
(Fig. 6A). However, when the thioglycollate-induced
peritoneal macrophages were pretreated with MTX in vitro
for 24 h and then stimulated with LPS, they produced more
proinflammatory cytokines (IL-6, TNF-α and IL-12p40).
The level of IL-10 was not affected by MTX treatment in
vitro (Fig. 6B).
In vitro effect of methotrexate on cytokine production
by RAW 246.7 macrophage cell line 
In the culture of RAW 264.7 cells stimulated in vitro
with LPS MTX at low concentration (1 or 10 µg/ml) 
did not affect the production of proinflammatory cytokines
(IL-6 and TNF-α) by that macrophage cell line. However,
in the presence of high concentration of MTX (100 µg/ml)
LPS stimulated RAW 264.7 cells produced less TNF-α and
IL-6 as compared to MTX-untreated cells. The level of 
IL-10 production by RAW 264.7 cells was decreased by
MTX in a dose dependent manner (Fig. 7A). When the
RAW 264.7 cells were treated with MTX (24 h culture 
in vitro) prior to stimulation with LPS they produced
significantly less cytokines tested (IL-6, TNF-α and IL-10;
IL-12p40 was not detectable) (Fig. 7B).
Discussion
Methotrexate is the most commonly used slow acting
immunosuppressive drug for RA and other autoimmune
diseases. In contrast to anticancer treatment (e.g. in acute
lymphoblastic leukemia), very low doses of MTX are given
weekly in RA (15-30 mg/week ≤ 0.3 mg/kg), as a standard
procedure [2]. However, high-dose MTX has been also used
in arthritis in the treatment of refractory juvenile rheumatoid
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arthritis [19]. The beneficial therapeutic effect of MTX in
RA has been shown to be associated with anti-inflammatory
properties of the drug, especially with the inhibition of
proinflammatory cytokines such as TNF-α [8]. 
Collagen-induced arthritis (CIA) in mice is a commonly
used animal experimental model for studying arthritis, 
the most relevant model to RA in humans. Collagen-
induced arthritis has been also used to examine the
immuno suppresive and anti-inflammatory properties of
MTX. The effects of MTX treatment on both clinical
symptoms and ex vivo activities of immune cells (macro -
phages, T cells, synoviocytes, epithelial cells) has been
studied in many laboratories. It is a common agreement that
MTX ameliorates the development CIA and is accompanied
with inhibition of the production of proinflammatory
mediators (cytokines, eicosanoids, NO). However, the major
target cell for MTX, the producer of cytokines, is still
controversial. Especially the data showing the effect of
MTX on macrophage activity ex vivo and in vitro are not
consistent. It has been shown that MTX does not affect, or
only slightly inhibits, the cytokine production by
macrophages, while it strongly inhibits the production of
T-cell cytokines [4, 15]. On the other hand, low-doses of
MTX significantly diminished the production of TNF-α,
IL-1 and IL-6 by human synovial macrophages [20]. The
differences between in vivo effects of MTX on human (RA)
and murine (CIA) macrophages may be explained by
treatment of mice with the doses of MTX not relevant to
those used for treatment of RA patients. 
In this study we have tested the MTX effect on cytokine
production by macrophages in three experimental systems: 
• MTX treatment of CIA in DBA/1J mice and ex vivo
cytokine release by residual peritoneal cells, 
• short-term in vivo MTX treatment of CBA mice and in
vitro examination of thioglycollate-induced peritoneal
macrophages, 
• in vitro incubation of MTX with either CBA mice
peritoneal macrophages or with RAW 264.7 cells (murine



























Fig. 5. The effect of short time in vivo MTX treatment on the cytokine production by CBA mice peritoneal macrophages  
CBA-mice received 3 intravenous injections of MTX (50 µg/mouse) every other day. Then thioglycollate was injected intraperitoneally to induce macrophages. Peri-
toneal macrophages were harvested three days later and the cells were cultured in vitro for 24 h in the presence of LPS (100 ng/ml). IL-6, TNF-α, IL-10 and 
IL-12p40 were measured in the culture supernatants by ELISA. White bars – untreated, black bars – MTX treated mice; *p < 0.05; ***p < 0.001, MTX treated vs.
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We have used high-dose MTX treatment in vivo (7.5 mg
MTX/kg/week) and in vitro (1, 10, 100 µg of MTX/ml),
according to the protocols used previously by Neurath, to
test MTX specific effects on proinflammatory cytokine
production in healthy and arthritic (CIA) mice [16]. 
Our studies clearly indicate that intravenous MTX
administration markedly ameliorates arthritis in CIA-
induced mice. The attenuation of clinical symptoms was
associated with the profound inhibition of anti-collagen II
immunoglobulin production. This therapeutic effect 
was similar to that observed by Neurath et al. after
intraperitoneal administration of MTX [16]. There was no
difference between the effect of MTX on Th1 and Th2
related IgG subclasses, IgG2a and IgG1, respectively, in
contrast to other studies, in which MTX selectively inhibited
Th1 response [21, 22]. It has been found that MTX
suppresses production of proinflammatory cytokines such
as IL-6, IL-1, TNF-α and IFN-γ in vitro, ex vivo and in vivo,
while production of the anti-inflammatory Th2 IL-4
cytokine was less affected [11]. Moreover, the production
of T-cell cytokines (TNF-α) was more affected than the
production of TNF-α by macrophages. It was the effect of
MTX on spleen cells taken from arthritic mice and activated
in vitro with either T-cell (anti-CD3/CD28 antibodies) or
macrophage (LPS – TLR4 ligand) stimuli [16, 23]. These
data suggest that TNF-α production by T cells is an
important target of MTX. In the present study we addressed
the question whether macrophages are the target cells for
MTX in arthritis. Surprisingly, we have found that MTX
treatment, starting prior to the CIA onset, resulted in the
enhancement of cytokine production (TNF-α, IL-6, IL-12)
by peritoneal cells stimulated in vitro with LPS, as compared
to cytokine production by cells taken from untreated
DBA/1J mice. This effect was also observed when
thioglycollate-induced peritoneal macrophages were taken
from CBA mice treated with MTX and compared with
control macrophages. Interestingly, the production of
proinflammatory cytokines (TNF-α, IL-6 and IL-12) was
more affected than that of anti-inflammatory IL-10. The






























Fig. 6. In vitro effect of MTX on cytokine production by thioglycollate-induced CBA peritoneal macrophages
A – Peritoneal macrophages were cultured in vitro in the presence of LPS (100 ng/ml) and various concentrations of MTX (0 – white bars, 1, 10 or 100 µg/ml –
gray to black bars) for 24 h or B – macrophages were cultured for 24 h in the presence of MTX and then stimulated with LPS for additional 24 h. 
IL-6, TNF-α, IL-12p40 and IL-10 were measured in the culture supernatant by ELISA; *p < 0.05; ***p < 0.001, MTX treated vs. untreated cells (Student’s t-test). 
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results were seen after the stimulation of macrophages with
zymosan (data not shown). These data suggest indirect in
vivo effect of MTX on macrophages. One may speculate
that in vivo MTX selectively inhibited some undetected
macrophage suppressor(s), what resulted in an enhancement
of the production of proinflammatory mediators such as
TNF-α, IL-6 and NO (not shown). On the other hand, there
exists a great body of evidence that MTX directly inhibits
proinflammatory functions of macrophages. It has been
shown that suppression of inflammation (thioglycollate-
induced peritonitis) by low-dose MTX is mediated by
activation of adenosine A2A receptor in peritoneal cells 
and by reduced leukocyte accumulation at a site of
inflammation. However, it has been also postulated that the
anti-inflammatory effects of MTX are mediated by different
receptors in different inflammatory loci or on different
inflammatory cells [24]. The latter hypothesis may explain
the observed dual effect of MTX treatment of CIA, the anti-
inflammatory effect on the development of arthritis and the
“proinflammatory” effect on peritoneal cells in DBA/1J
mice. To investigate the direct effect of high-dose MTX on
cytokine production by macrophages we extended our
studies on in vitro experimental model. Interestingly, MTX
(1-100 µg/ml), added to CBA mice peritoneal macrophages
simultaneously with LPS, did not inhibit the production of
proinflammatory cytokines and in some experiments it even
slightly enhanced this production. Finally, we have tested
in vitro the influence of MTX on RAW macrophages. We
have used macrophage cell line for two reasons. First, we
wanted to avoid the presence of additional inflammatory
cells, which could be the primarily target of MTX. Second,
in contrast to peritoneal macrophages, RAW macrophages
are proliferating cells. Therefore, MTX may halt
proliferation of these dividing cells at G1 phase of the cell
cycle, similarly to its action on macrophage synoviocytes
in arthritic joints. We have found that MTX markedly
suppresses production of proinflammatory cytokines when
pre-incubated with proliferating RAW cells for 24 h before
their stimulation with either LPS or zymosan (data not
shown).
In conclusion, the data reported here provide evidence
that high-dose MTX-treatment markedly ameliorates
arthritis while it does not suppress the cytokine release from
peritoneal macrophages. It may suggest different biological
targets for MTX (e.g. synoviocytes vs. peritoneal
macrophages). Moreover, the in vitro study clearly indicates
that MTX can inhibit the cytokine production if target cells
proliferate. However, further studies are necessary to explain
the mechanism of MTX-dependent sensitization of
peritoneal macrophages to enhanced production of
proinflammatory mediators. 
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Fig. 7. The effect of MTX on the production of cytokines by
RAW 264.7 macrophage cell line 
A – RAW 264.7 cells were cultured in vitro in the presence of LPS (100 ng/ml)
and different concentrations of MTX (0 – white bars, 1, 10 or 100 µg/ml – gray
to black bars) for 24 h.  B – RAW 264.7 cells were cultured for 24 h in the pres-
ence of MTX and then stimulated with LPS for additional 24h. IL-6, TNF-α
and IL-10 were measured in the culture supernatant by ELISA. 
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